VEGF, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG
Search, find, compare suppliers for anti-VEGF, Human antibody, protein, ELISA kits.
| Edit | |
|---|---|
| Antigenic Specificity | VEGF, Human |
| Clone | REAL1004 |
| Host Species | Recombinant Human |
| Reactive Species | human |
| Isotype | n/a |
| Format | phycoerythrin (PE) conjugate |
| Size | 200 µL |
| Concentration | n/a |
| Applications | MICS (MACSima Imaging Cyclic Staining), Immunohistochemistry, Immunofluorescence |
| Reviews / Ratings | If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY. |
| Description | VEGF Antibody, anti-human, PE, REAdye_lease™. Clone REAL1004 is an antibody fragment derived from the full VEGF antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity. | Clone REAL1004 recognizes the VEGF protein, also known as VEGFA (Vascilar Endothelial Growth Factor), a member of the PDGF/VEGF growth factor family and is essential for both physiological and pathological angiogenesis. Alternatively spliced transcript variants encoding different isoforms have been described. The gene is upregulated in many known tumors and its expression is correlated with tumor stage and progression. Allelic variants of the gene have been associated with microvascular complications of diabetes 1 (MVCD1) and atherosclerosis. | For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675). |
| Immunogen | n/a |
| Other Names | VEGF-A, Vascular Endothelial Growth Factor |
| Gene, Accession # | n/a |
| Catalog # | 130-127-122 |
| Price | $470 |
| Order / More Info | VEGF, Human Antibody from MILTENYI BIOTEC B.V. & Co. KG |
| Product Specific References | Terme, M. et al. (2013) VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer. Cancer Res. 73 (2): 539-549. | Claesson-Welsh, L. et al. (2013) VEGFA and tumour angiogenesis. J Intern Med 273 (2): 114-127. |
MILTENYI BIOTEC B.V. & Co. KG
MILTENYI BIOTEC B.V. & Co. KG
Friedrich-Ebert-StraÃe 68
51429 Bergisch Gladbach GERMANY
P: +49 2204 8306-0
F: +49 2204 85197
macs@miltenyibiotec.de
https://www.miltenyibiotec.com
Profile of MILTENYI BIOTEC B.V. & Co. KG